To ask the Secretary of State for Health, whether he plans to appeal NICE's draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.
19 October 2016
The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.
There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.